Investors

Egetis Therapeutics is committed to creating long-term shareholder value through the development and commercialization of innovative treatments for rare diseases with significant unmet medical needs. The Company is listed on the Nasdaq Stockholm main list and strives to provide shareholders, analysts, and the wider financial market with timely and reliable information.

Market cap above represents the market value of the shares admitted to trading on Nasdaq Stockholm and excludes C-shares.